The North America Castrate-resistant Prostate Cancer Market would witness market growth of 7.5% CAGR during the forecast period (2020-2026). The cases of castrate-resistant prostate cancer are increasing across the world due to the high prevalence of prostate cancer that grows into castrate-resistant prostate cancer in the later years of diagnosis. There are millions of men who get diagnosed with the disease every year in the US. However, Metastatic castrate-resistant Prostate Cancer has been increasing at a significant rate. Better prognosis is associated with the increasing trend of initial diagnosis of the condition. These rising cases of castrate-resistance prostate cancer patients around the globe have driven the market growth, which further increases its demand.
Prostate cancer is a type of cancer that develops into male reproductive systems. Generally, prostate cancer is slow-growing and stable but it may spread from the prostate (gland) to different part of the body like bone and lymph node. In the beginning, prostate cancer does not show any kind of symptom but in some serious cases, it causes pain during urination and can even cause a problem during sexual intercourse. Castration-resistant prostate cancer referred to prostate cancer that reached other body parts and resists medical or surgical treatment.
The high-risk factor for castration-resistant prostate cancer involves the geriatric population, genetic predisposition, medication exposure, unhygienic diet, and many sexual partners. Detection of castration-resistant prostate cancer is done by prostate imaging, tumor marker, biopsy, and staging test. The main thing about castration-resistant prostate cancer is that it’s resistance to medical and surgical treatment. Although, there are various available options in the market such as hormone therapy, antiangiogenic treatment, immune modulation, and bone targeted therapies.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in North America is expected to register a CAGR of 7.5% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Radiotherapy
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 North America Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. North America Castrate-resistant Prostate Cancer Market by Therapy
4.1 North America Hormonal Therapy Market by Country
4.2 North America Immunotherapy Market by Country
4.3 North America Chemotherapy Market by Country
4.4 North America Radiotherapy Market by Country
Chapter 5. North America Castrate-resistant Prostate Cancer Market by Country
5.1 US Castrate-resistant Prostate Cancer Market
5.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
5.2 Canada Castrate-resistant Prostate Cancer Market
5.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
5.3 Mexico Castrate-resistant Prostate Cancer Market
5.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
5.4 Rest of North America Castrate-resistant Prostate Cancer Market
5.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
TABLE 1 North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 2 North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 North America Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 6 North America Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 7 North America Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 8 North America Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 9 North America Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 10 North America Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 11 North America Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 12 North America Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 13 North America Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 14 North America Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 15 US Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 US Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 US Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 US Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 Canada Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 20 Canada Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 21 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 22 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 23 Mexico Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 24 Mexico Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 25 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 26 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 27 Rest of North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 28 Rest of North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 29 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 30 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 31 Key Information – Sanofi S.A.
TABLE 32 Key information –Johnson and Johnson
TABLE 33 Key Information – Pfizer, Inc.
TABLE 34 Key Information – Bayer AG
TABLE 35 Key Information – Abbott Laboratories
TABLE 36 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 37 Key Information – Northwest Biotherapeutics, Inc.
TABLE 38 Key Information – Active Biotech AB
TABLE 39 key information – Astellas Pharma, Inc.
TABLE 40 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research